Wave Life Sciences prices upsized $402.5M public offering; extends cash runway to Q3 2028

Wave Life Sciences Ltd.

Offering: 15,789,475 shares at $19.00 plus 2,631,578 pre-funded warrants at $18.9999.
Underwriters fully exercised option for additional 2,763,157 shares; total gross proceeds ~$402.5M.
Closing expected Dec 11, 2025; pro forma shares outstanding ~187.7M.
Cash runway extended into Q3 2028; excludes potential milestone payments from GSK collaboration.
Jefferies, Leerink Partners, BofA Securities act as joint book-running managers.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Wave Life Sciences Ltd. entered into Underwriting Agreement with Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc. valued at approximately $402.5 million (effective 2025-12-09).

Action: entry
Agreement: underwriting
Counterparty: Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc.
Value: approximately $402.5 million
Effective: 2025-12-09

Exact text from the filing

On December 9, 2025, Wave Life Sciences Ltd. (the “Company,” “we” or “us”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC, Leerink Partners LLC and BofA Securities, Inc., as representatives of the several underwriters named therein

View on SEC.gov

Browse all material agreements →

Wave Life Sciences Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-25-314746

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.